Author:
Veeraraghavan Jamunarani,De Angelis Carmine,Reis-Filho Jorge S.,Pascual Tomás,Prat Aleix,Rimawi Mothaffar F.,Osborne C. Kent,Schiff Rachel
Funder
NIH
Cancer Center
Breast Cancer Research Foundation
Cancer Prevention & Research Institute of Texas
The Conquer Cancer Foundation
Instituto de Salud Carlos III
Susan Komen Foundation
NIH/NCI Cancer Center
AstraZeneca and GlaxoSmithKline
GlaxoSmithKline and Genentech
Nanostring Technologies
Reference85 articles.
1. Targeting HER2 for the treatment of breast cancer;Rimawi;Annu Rev Med,2015
2. HER2: biology, detection, and clinical implications;Gutierrez;Arch Pathol Lab Med,2011
3. EGF-ERBB signalling: towards the systems level;Citri;Nat Rev Mol Cell Biol,2006
4. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial;Baselga;Lancet,2012
5. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015
Cited by
47 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献